New REDUCE-IT ® Analyses Show VASCEPA ®/VAZKEPA ® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups By Investing.com
Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp(a) Results Published Simultaneously in ...
